Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

BACKGROUND: The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell–receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Byrd, John C., Furman, Richard R., Coutre, Steven E., Flinn, Ian W., Burger, Jan A., Blum, Kristie A., Grant, Barbara, Sharman, Jeff P., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Sukbuntherng, Juthamas, Chang, Betty Y., Clow, Fong, Hedrick, Eric, Buggy, Joseph J., James, Danelle F., O'Brien, Susan
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3772525/
https://ncbi.nlm.nih.gov/pubmed/23782158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1215637
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados